Bevacizumab/interferon: Better than interferon alone for renal cell carcinoma?
Targeted RCC therapy boosts progression-free survival but not overall survival
Publish date: December 1, 2009
Wayne Kuznar
Wayne Kuznar
Bevacizumab added to interferon-alpha as initial systemic therapy for metastatic renal cell carcinoma did not significantly improve overall survival compared to interferon alone, but did significantly increase progression-free survival.